

Supplementary Appendix

Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study

Table of contents

Supplementary Table S1. Eligibility criteria and covariates definition.....	2
Supplementary Table S2. Definitions and ICD-10 codes for the main and secondary outcomes and the comorbidity covariates ^a	4
Supplementary Figure S1. Schematic figure of the study design.....	5
Supplementary Table S3: Number of events and person-years within 28 days after vaccination with a bivalent omicron-containing vaccine as a fourth dose by type of vaccine and reference period in Danish 50+ year-olds during 15 September 2022 to 10 December 2022. ^a	6
Supplementary Table S4: Risk of adverse events within 28 days after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 using an alternative analytical approach of a self-controlled case series design.....	8
Supplementary Table S5: Risk of adverse events within 28 days after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 using an alternative analytical approach of an observed vs expected design.....	9
Supplementary Table S6: Risk of severe adverse events (hospitalization for ≥ 5 hours) within 28 days after vaccination with a bivalent omicron-containing vaccine as a fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.	10
Supplementary Table S7: Sensitivity analysis of the associated risk of adverse events within 28 days following fourth dose bivalent omicron-containing booster vaccination where including both primary and secondary diagnoses in the outcome definitions.....	11
Supplementary Table S8. Risk of adverse events after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 with use of alternative risk periods.	12
Supplementary Table S9: Risk of cerebrovascular infarction, myocarditis and/or pericarditis after vaccination with the individual bivalent omicron-containing vaccine types as a fourth dose by sex and age groups within 28 days in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.	15
Supplementary references	18

Supplementary Table S1. Eligibility criteria and covariates definition.

Variable	Details
Eligibility criteria	
Age of 50 years or older	<i>The Civil Registration System</i> ¹ . Defined by time birthyear and year 2022. National vaccine policy of fourth dose rollout, individuals had to be born in year 1972 or earlier.
Vaccinated with a primary course and one booster Covid-19.	<i>The Danish Vaccination Register</i> ² . Defined as registered received three previous Covid-19 vaccines with the BNT162b2 and/or mRNA-1273 as well as and/or AZD1222 vaccine (the latter as part of the primary vaccination course only). Other vaccine types were rare within our study population. During the national rollout of the primary vaccination course, vaccination with the AZD1222 vaccine was halted in Denmark in early March 2021.
Third vaccine dose not received earlier than 9 September 2021 ^a	<i>The Danish Vaccination Register</i> ² . First day of national rollout of the third (i.e., first booster vaccine dose) to the general Danish population.
Third vaccine dose not received within 90 days of the second dose ^b	<i>The Danish Vaccination Register</i> ² . As vaccination with a third vaccine dose within 90 days of the primary vaccination schedule does not constitute as a booster dose per se, but rather a part of the primary vaccination schedule.
Covariates	
Ethnicity	<i>The Civil Registration System</i> ¹ . Defined by registered place of birth and categorized according Nordic (Denmark, Finland, Norway, or Sweden), Western (rest of Europe, united states, Australia or New Zealand), and non-Western countries (all others).
Region of residency	<i>The Civil Registration System</i> ¹ . Defined by the last registered address at baseline (1 January 2021) and grouped according: Northern Denmark Region, Central Denmark Region, Region of Southern Denmark, Capital Region of Denmark, and Region Zealand.
Vaccination priority groups	<i>The Danish Vaccination Register</i> ² . The Danish Health Agency have provided the governmentally assigned Covid-19 vaccine priority groups that were among other prioritized according to high risk of severe Covid-19 (yes/no; last update 24 May 2021).
Comorbidities	
Asthma	ICD-10 codes: J45, J46
Chronic respiratory disorder	ICD-10 codes: E84, J41-J44, J47, J84
Chronic cardiac disorder	ICD-10 codes: I05-I08, I20-I28, I34-I37, I42-I51
Renal disorder	ICD-10 codes: N03, N05, N07, N18, N19, N25, N26, N27
Diabetes	ICD-10 codes: E10-E14
Autoimmune disorder	ICD-10 codes: D510, D590, D591, D690, D693, D86, E035, E039, E050, E055, E059, E063, E065, E271, E272, E310, G04, G131, G35, G36, G61, G700, H20, I00, I02, K50,

K51, K732, K743, K900, L10, L12, L130, L40, L63, L80, M05, M06, M08, M30, M311, M313, M315, M316, M317, M32-M34, M350, M351-M353, M358, M359, M45, M60

Epilepsy ICD-10 codes: G40, G41

Malignancy ICD-10 codes: C00-C96 (not C44), D70-D72, D730, D81-D84

Psychiatric disorder ICD-10 codes: F00-F99

ICD-10 denotes International Classification of Diseases System, version 10. ^aSimilarly, we censored individuals vaccinated with a fourth dose prior to 15 September 2022 (first day of national rollout of the fourth vaccine dose to the general population). ^bSimilarly, we censored individuals receiving a fourth dose within 90 days of the third dose. We also excluded individuals with history of the respective outcome under studied prior to the follow-up period.


Supplementary Table S2. Outcome definitions.

Outcomes	ICD-10 codes
Anaphylaxis	T782, T783, T805, T886
Ischemic cardiac event	I20-I251
Cerebrovascular event	I60-66, G450-G453
Cerebrovascular infarction (incl. TIA) ^b	I63, I64, G450-453
Arterial thromboembolism	I74
Deep venous thrombosis	I80-82 (not I800, I808C, or I821)
Pulmonary embolism	I26
Myocarditis or pericarditis	I300, I308, I309, I328, I401, I408, I409, I418, I514
Myocarditis ^b	I401, I408, I409, I418, I514
Pericarditis ^b	I300, I308, I309, I328
Cerebral venous thrombosis	I636, I676
Thrombocytopenia or coagulative disorders	D65, D683, D686, D688-689, D690, D693-D699 (not D697 or D698A)
Guillain-Barré syndrome	G610
Bell's palsy	G510
Transverse myelitis	G373
Encephalomyelitis or encephalitis	G040, G040A, G048, G049, G058, G361
Narcolepsy	G474
Appendicitis	K35-K37
Aseptic arthritis	M10, M119, M130, M131, M139
Type 1 diabetes mellitus	E10
Subacute thyroiditis	E061
Heart failure	I110, I420, I426-I429, I50, J81,
Arrhythmia	I44-I49
Acute liver failure	K71, K72
Acute kidney failure	D593, I12, I13, N00-N02, N04-N05, N08, N10, N141, N142, N144, N17, N19, R34
Acute pancreatitis	K850, K853, K858, K859
Erythema multiforme	L51
Seizure	G40, G41
Arterial Aneurysm	I71, I72
Uveitis	H20, H30


ICD-10 denotes International Classification of Diseases System, version 10, TIA transient cerebral ischemic attack, and NA not applicable; information on death was gathered from the Danish Civil Registration System. ^aDiagnoses were identified through use of the Danish National Patient Register. Only diagnoses registered as primary diagnoses were included in the outcome definitions, however, secondary diagnoses were included in a sensitivity analysis. Main outcome definition included any hospital contact, whereas in a sensitivity analysis we defined severe adverse events as by hospital contacts with a duration of ≥ 5 hours ^bExamined separately post-hoc.

Supplementary Figure S1. Schematic figure of the study design.

A. Individual not receiving a fourth dose



B. Individual receiving a fourth dose



Supplementary Table S3: Number of events and person-years within 28 days after vaccination with a bivalent omicron-containing vaccine as a fourth dose by type of vaccine and reference period in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.^a

Outcome event	Number of events / person-years			Reference period
	BNT BA.4-5-containing	BNT BA.1-containing	MOD BA.1-containing	
Anaphylaxis	22 / 85780.6	7 / 40100.1	1 / 4278.8	363 / 1891644.8
Ischemic cardiac event	425 / 83391.3	227 / 38670.0	20 / 4134.8	9992 / 1838445.5
Cerebrovascular event	468 / 84037.0	305 / 38670.9	25 / 4176.9	11523 / 1847731.6
Arterial thromboembolism	17 / 85808.8	4 / 40112.2	0 / 4280.3	385 / 1892133.7
Deep vein thrombosis	140 / 85065.6	90 / 39674.8	7 / 4247.2	3593 / 1875648.1
Pulmonary embolism	125 / 85349.3	86 / 39774.9	5 / 4253.2	3336 / 1881117.3
Myocarditis or pericarditis	18 / 85799.8	9 / 40116.3	2 / 4280.8	322 / 1892114.4
Cerebral venous thrombosis	2 / 85864.3	1 / 40148.7	0 / 4283.3	37 / 1893510.4
Thrombocytopenia and coagulative disorders	18 / 85748.0	10 / 40077.3	2 / 4277.4	489 / 1890679.3
Guillain-Barré syndrome	1 / 85860.5	0 / 40147.6	0 / 4283.4	48 / 1893425.3
Bell's palsy	19 / 85777.8	9 / 40106.3	1 / 4278.7	449 / 1891679.3
Transverse myelitis	NE	NE	NE	13 / 1893596.9
Encephalomyelitis or encephalitis	6 / 85857.0	2 / 40141.9	1 / 4283.1	67 / 1893277.3
Narcolepsy	NE	NE	NE	7 / 1893483.6
Appendicitis	81 / 85457.2	39 / 39953.9	6 / 4263.6	1911 / 1885284.3
Aseptic arthritis	123 / 85007.9	87 / 39608.3	5 / 4238.1	3213 / 1873648.6
Type 1 diabetes mellitus	13 / 85188.1	10 / 39809.1	1 / 4244.2	559 / 1878618.9
Subacute thyroiditis	10 / 85841.3	6 / 40141.7	0 / 4282.4	138 / 1893045.7
Heart failure	305 / 84375.4	200 / 39005.9	8 / 4196.3	8409 / 1855723.5
Arrhythmia	925 / 80698.5	561 / 36316.3	44 / 3943.1	21642 / 1769323.7
Acute liver failure	7 / 85821.6	3 / 40122.7	0 / 4280.1	375 / 1892421.8
Acute kidney failure	124 / 85300.9	103 / 39704.3	9 / 4245.7	3819 / 1878542.3
Acute pancreatitis	43 / 85654.8	30 / 40021.5	4 / 4272.8	1256 / 1888827.6

Supplementary Table S3: Number of events and person-years within 28 days after vaccination with a bivalent omicron-containing vaccine as a fourth dose by type of vaccine and reference period in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.^a

Outcome event	Number of events / person-years			Reference period
	BNT BA.4-5-containing	BNT BA.1-containing	MOD BA.1-containing	
Erythema multiforme	1 / 85866.0	0 / 40148.9	0 / 4283.6	36 / 1893528.2
Seizure	55 / 85326.4	53 / 39735.5	3 / 4254.2	1788 / 1879652.3
Arterial aneurysm	180 / 85021.6	106 / 39579.0	12 / 4228.2	3566 / 1874302.8
Uveitis	19 / 85722.3	12 / 40077.7	0 / 4277.7	622 / 1890418.3

BNT denotes BNT162b2, MOD mRNA-1273, and NE not estimable. ^aThe corresponding incidence rate ratios with 95% confidence intervals are shown in Figure 2.

Supplementary Table S4: Risk of adverse events within 28 days after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 using an alternative analytical approach of a self-controlled case series design.

Outcome event	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Anaphylaxis	30 / 47.6	347 / 673.7	1.05 (0.67-1.65)
Ischemic cardiac event	672 / 1354.5	9726 / 18814.4	0.92 (0.84-1.01)
Cerebrovascular event	798 / 1329.4	11291 / 19290.0	0.96 (0.89-1.05)
Arterial thromboembolism	21 / 38.8	371 / 621.2	1.15 (0.67-1.96)
Deep vein thrombosis	237 / 448.4	3460 / 6502.5	1.01 (0.86-1.18)
Pulmonary embolism	216 / 369.8	3234 / 5518.4	0.85 (0.72-1.00)
Myocarditis or pericarditis	29 / 38.6	314 / 597.8	1.52 (0.94-2.45)
Cerebral venous thrombosis	3 / 4.5	36 / 64.3	1.49 (0.31-7.10)
Thrombocytopenia or coagulative disorder	30 / 52.9	466 / 834.7	0.87 (0.57-1.34)
Guillain-Barré syndrome	1 / 4.4	48 / 71.5	0.20 (0.03-1.57)
Bell's palsy	29 / 53.9	435 / 793.4	0.96 (0.62-1.51)
Transverse myelitis	0 / 1.9	13 / 26.7	NE
Encephalomyelitis or encephalitis	9 / 7.7	66 / 125.1	1.66 (0.68-4.07)
Narcolepsy	0 / 1.0	6 / 14.3	NE
Appendicitis	126 / 260.6	1856 / 3607.4	0.97 (0.78-1.21)
Aseptic arthritis	215 / 431.6	3090 / 6130.2	0.92 (0.78-1.09)
Type 1 diabetes mellitus	24 / 72.0	538 / 1038.5	0.81 (0.50-1.31)
Subacute thyroiditis	16 / 16.6	131 / 257.1	1.97 (0.99-3.91)
Heart failure	513 / 921.7	8160 / 13543.2	0.80 (0.72-0.89)
Arrhythmia	1530 / 2777.5	20846 / 38150.4	0.93 (0.87-0.99)
Acute liver failure	10 / 31.6	368 / 533.3	0.37 (0.19-0.74)
Acute kidney failure	236 / 362.7	3736 / 5670.7	0.79 (0.68-0.92)
Acute pancreatitis	77 / 146.5	1224 / 2107.8	0.82 (0.63-1.07)
Erythema multiforme	1 / 3.7	36 / 59.7	0.43 (0.05-3.76)
Seizure	111 / 210.1	1707 / 3053.6	0.89 (0.71-1.12)
Arterial aneurysm	298 / 468.9	3429 / 6322.4	0.94 (0.82-1.09)
Uveitis	31 / 76.8	600 / 1124.9	0.97 (0.63-1.49)

NE denotes not estimable.

Supplementary Table S5: Risk of adverse events within 28 days after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 using an alternative analytical approach of an observed vs expected design.

Outcome event	Number of observed / expected events	Rate ratio (95% CI)
	Bivalent boosters	
Anaphylaxis	30 / 38.3	0.78 (0.53-1.12)
Ischemic cardiac event	672 / 1123.5	0.60 (0.55-0.65)
Cerebrovascular event	798 / 845.2	0.94 (0.88-1.01)
Arterial thromboembolism	21 / 36.6	0.57 (0.35-0.88)
Deep vein thrombosis	237 / 322.3	0.74 (0.64-0.84)
Pulmonary embolism	216 / 269.7	0.80 (0.70-0.92)
Myocarditis or pericarditis	29 / 21.6	1.35 (0.90-1.93)
Cerebral venous thrombosis	3 / 2.7	1.12 (0.23-3.28)
Thrombocytopenia or coagulative disorder	30 / 74.4	0.40 (0.27-0.58)
Guillain-Barré syndrome	1 / 5.8	0.17 (0.00-0.97)
Bell's palsy	29 / 33.2	0.87 (0.59-1.26)
Transverse myelitis	0 / 1.3	NE
Encephalomyelitis or encephalitis	9 / 7.7	1.17 (0.54-2.23)
Narcolepsy	0 / 4.0	NE
Appendicitis	126 / 110.1	1.14 (0.95-1.36)
Aseptic arthritis	215 / 347.5	0.62 (0.54-0.71)
Type 1 diabetes mellitus	24 / 402.3	0.06 (0.04-0.09)
Subacute thyroiditis	16 / 7.2	2.22 (1.27-3.60)
Heart failure	513 / 937.4	0.55 (0.50-0.60)
Arrhythmia	1530 / 2467.1	0.62 (0.59-0.65)
Acute liver failure	10 / 44.4	0.23 (0.11-0.41)
Acute kidney failure	236 / 260.0	0.91 (0.80-1.03)
Acute pancreatitis	77 / 87.4	0.88 (0.70-1.10)
Erythema multiforme	1 / 3.0	0.33 (0.01-1.83)
Seizure	111 / 349.3	0.32 (0.26-0.38)
Arterial aneurysm	298 / 392.9	0.76 (0.67-0.85)
Uveitis	31 / 56.7	0.55 (0.37-0.78)

NE denotes not estimable.

Supplementary Table S6: Risk of severe adverse events (hospitalization for ≥5 hours) within 28 days after vaccination with a bivalent omicron-containing vaccine as a fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.

Outcome event	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Anaphylaxis	20 / 130178	217 / 1891849	1.16 (0.68-2.01)
Ischemic cardiac event	513 / 126464	8188 / 1841576	0.90 (0.81-1.00)
Cerebrovascular event	683 / 127072	9990 / 1849868	0.94 (0.86-1.03)
Arterial thromboembolism	14 / 130212	271 / 1892266	0.91 (0.49-1.70)
Deep vein thrombosis	88 / 129263	1327 / 1878842	0.97 (0.76-1.25)
Pulmonary embolism	148 / 129461	2556 / 1882073	0.75 (0.62-0.91)
Myocarditis or pericarditis	20 / 130204	263 / 1892203	1.18 (0.69-2.03)
Cerebral venous thrombosis	3 / 130297	29 / 1893523	2.10 (0.43-10.15)
Thrombocytopenia and coagulative disorders	9 / 130135	220 / 1891056	0.70 (0.33-1.48)
Guillain-Barré syndrome	1 / 130292	41 / 1893436	0.23 (0.03-1.84)
Bell's palsy	11 / 130193	166 / 1892014	1.16 (0.56-2.41)
Transverse myelitis	0 / 130305	5 / 1893609	NE
Encephalomyelitis or encephalitis ^a	9 / 130284	50 / 1893304	2.67 (1.01-7.07)
Appendicitis	126 / 129677	1897 / 1885316	1.03 (0.83-1.27)
Aseptic arthritis	40 / 129171	786 / 1877282	0.78 (0.54-1.12)
Type 1 diabetes mellitus	4 / 129297	133 / 1879275	0.70 (0.23-2.16)
Subacute thyroiditis	0 / 130280	6 / 1893231	NE
Heart failure	317 / 127945	5418 / 1859868	0.75 (0.66-0.85)
Arrhythmia	904 / 122126	12768 / 1782238	0.90 (0.83-0.98)
Acute liver failure	9 / 130238	260 / 1892577	0.45 (0.22-0.93)
Acute kidney failure	188 / 129322	3183 / 1879340	0.75 (0.64-0.89)
Acute pancreatitis	74 / 129955	1209 / 1888900	0.82 (0.62-1.07)
Erythema multiforme	0 / 130300	19 / 1893553	NE
Seizure	59 / 129434	830 / 1881012	0.91 (0.67-1.24)
Arterial aneurysm	76 / 129152	1017 / 1877798	1.00 (0.76-1.31)
Uveitis	6 / 130142	67 / 1891200	1.35 (0.49-3.74)

NE denotes not estimable. ^aThe rate ratio for encephalomyelitis or encephalitis was 1.55 (95% CI 0.71-2.95) and 2.77 (95% CI 0.99-7.75) with use of observed vs. expected and self-controlled case series analysis, respectively.

Supplementary Table S7: Sensitivity analysis of the associated risk of adverse events within 28 days following fourth dose bivalent omicron-containing booster vaccination where including both primary and secondary diagnoses in the outcome definitions.

Outcome	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Anaphylaxis	31 / 130156	400 / 1891605	0.92 (0.60-1.39)
Ischemic cardiac event	742 / 126093	10864 / 1837213	0.96 (0.88-1.04)
Cerebrovascular event	875 / 126740	12807 / 1846000	0.95 (0.88-1.03)
Arterial thromboembolism	22 / 130197	425 / 1892073	0.88 (0.54-1.45)
Deep vein thrombosis	258 / 128938	4069 / 1875052	0.93 (0.80-1.08)
Pulmonary embolism	238 / 129339	3839 / 1880619	0.80 (0.69-0.93)
Myocarditis or pericarditis	32 / 130192	379 / 1892054	1.28 (0.83-1.97)
Cerebral venous thrombosis	3 / 130296	40 / 1893506	1.58 (0.36-6.92)
Thrombocytopenia and coagulative disorders	45 / 130087	700 / 1890477	0.81 (0.57-1.14)
Guillain-Barré syndrome	3 / 130291	55 / 1893417	0.64 (0.18-2.30)
Bell's palsy	29 / 130160	472 / 1891644	0.94 (0.61-1.45)
Transverse myelitis	1 / 130303	14 / 1893595	1.10 (0.10-12.18)
Encephalomyelitis or encephalitis	11 / 130280	77 / 1893261	1.80 (0.81-4.00)
Narcolepsy	2 / 130295	14 / 1893476	1.05 (0.19-5.73)
Appendicitis	129 / 129670	1953 / 1885224	1.01 (0.82-1.25)
Aseptic arthritis	251 / 128767	3953 / 1872615	0.85 (0.73-0.98)
Type 1 diabetes mellitus	41 / 129197	936 / 1878074	0.80 (0.56-1.14)
Subacute thyroiditis	17 / 130265	143 / 1893038	1.60 (0.86-2.98)
Heart failure	609 / 127366	10584 / 1853124	0.74 (0.68-0.82)
Arrhythmia	1903 / 120307	27536 / 1761569	0.91 (0.87-0.96)
Acute liver failure	15 / 130219	498 / 1892336	0.43 (0.25-0.75)
Acute kidney failure	386 / 129071	6185 / 1876334	0.81 (0.72-0.91)
Acute pancreatitis	83 / 129939	1358 / 1888695	0.80 (0.62-1.03)
Erythema multiforme	1 / 130298	41 / 1893522	0.40 (0.05-3.36)
Seizure	128 / 129282	2084 / 1879244	0.87 (0.71-1.07)
Arterial aneurysm	335 / 128752	4149 / 1873400	0.95 (0.83-1.08)
Uveitis	32 / 130073	653 / 1890363	0.85 (0.57-1.28)

Supplementary Table S8. Risk of adverse events after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 with use of alternative risk periods.

Alternative risk period/outcome	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Risk period restricted to the first 7 days after fourth vaccine dose			
Anaphylaxis	7 / 33083	398 / 2115427	0.93 (0.43-2.00)
Ischemic cardiac event	148 / 32081	11217 / 2055979	0.83 (0.70-0.98)
Cerebrovascular event	166 / 32256	12902 / 2066397	0.79 (0.67-0.92)
Arterial thromboembolism	6 / 33093	428 / 2115978	1.09 (0.47-2.50)
Deep vein thrombosis	60 / 32786	3998 / 2097555	0.97 (0.74-1.26)
Pulmonary embolism	35 / 32886	3768 / 2103658	0.55 (0.39-0.77)
Myocarditis or pericarditis	9 / 33092	368 / 2115955	1.55 (0.77-3.09)
Cerebral venous thrombosis	2 / 33117	43 / 2117512	4.43 (0.89-22.12)
Thrombocytopenia or coagulative disorder	9 / 33068	536 / 2114346	0.96 (0.49-1.89)
Guillain-Barré syndrome	0 / 33116	56 / 2117417	NE
Bell's palsy	10 / 33084	495 / 2115469	1.36 (0.71-2.62)
Transverse myelitis	0 / 33119	13 / 2117610	NE
Encephalomyelitis or encephalitis	1 / 33114	79 / 2117253	0.56 (0.07-4.12)
Narcolepsy	0 / 33117	7 / 2117482	NE
Appendicitis	33 / 32960	2118 / 2108328	1.04 (0.73-1.48)
Aseptic arthritis	56 / 32752	3616 / 2095306	0.94 (0.71-1.23)
Type 1 diabetes mellitus	12 / 32850	611 / 2100857	1.72 (0.94-3.15)
Subacute thyroiditis	4 / 33109	162 / 2116997	1.41 (0.50-3.96)
Heart failure	127 / 32430	9345 / 2075325	0.82 (0.69-0.98)
Arrhythmia	352 / 30760	24219 / 1978552	0.86 (0.77-0.95)
Acute liver failure	4 / 33099	404 / 2116300	0.73 (0.27-2.01)
Acute kidney failure	45 / 32853	4213 / 2100785	0.61 (0.45-0.83)
Acute pancreatitis	19 / 33029	1392 / 2112285	0.84 (0.52-1.33)
Erythema multiforme	0 / 33118	42 / 2117532	NE
Seizure	34 / 32869	1985 / 2102039	1.08 (0.76-1.54)
Arterial aneurysm	62 / 32748	4025 / 2095996	0.81 (0.62-1.04)
Uveitis	4 / 33062	689 / 2114067	0.45 (0.16-1.21)
Risk period restricted to the first 14 days after fourth vaccine dose			
Anaphylaxis	14 / 65919	388 / 2040463	0.92 (0.52-1.62)
Ischemic cardiac event	319 / 63920	10833 / 1983109	0.89 (0.79-1.00)

Supplementary Table S8. Risk of adverse events after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 with use of alternative risk periods.

Alternative risk period/outcome	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Cerebrovascular event	386 / 64268	12436 / 1993146	0.92 (0.83-1.03)
Arterial thromboembolism	12 / 65940	415 / 2040993	1.11 (0.60-2.06)
Deep vein thrombosis	120 / 65328	3863 / 2023219	0.97 (0.80-1.17)
Pulmonary embolism	103 / 65526	3614 / 2029108	0.82 (0.66-1.00)
Myocarditis or pericarditis	20 / 65938	351 / 2040972	1.88 (1.13-3.11)
Cerebral venous thrombosis	3 / 65988	38 / 2042474	3.78 (0.88-16.17)
Thrombocytopenia or coagulative disorder	18 / 65891	516 / 2039421	0.96 (0.58-1.58)
Guillain-Barré syndrome	0 / 65986	55 / 2042383	NE
Bell's palsy	15 / 65921	480 / 2040502	1.00 (0.58-1.73)
Transverse myelitis	0 / 65992	13 / 2042568	NE
Encephalomyelitis or encephalitis	4 / 65981	76 / 2042224	1.18 (0.40-3.47)
Narcolepsy	0 / 65988	7 / 2042446	NE
Appendicitis	68 / 65675	2044 / 2033610	1.08 (0.84-1.40)
Aseptic arthritis	109 / 65260	3478 / 2021054	0.90 (0.74-1.11)
Type 1 diabetes mellitus	17 / 65455	594 / 2026411	1.20 (0.71-2.02)
Subacute thyroiditis	8 / 65972	153 / 2041976	1.46 (0.67-3.17)
Heart failure	259 / 64616	9035 / 2001763	0.83 (0.72-0.94)
Arrhythmia	744 / 61282	23357 / 1908464	0.90 (0.83-0.97)
Acute liver failure	8 / 65952	389 / 2041304	0.72 (0.35-1.51)
Acute kidney failure	115 / 65460	4079 / 2026337	0.78 (0.64-0.95)
Acute pancreatitis	37 / 65813	1348 / 2037430	0.80 (0.57-1.13)
Erythema multiforme	0 / 65989	41 / 2042494	NE
Seizure	53 / 65492	1931 / 2027542	0.82 (0.61-1.09)
Arterial aneurysm	147 / 65250	3862 / 2021732	0.97 (0.81-1.15)
Uveitis	9 / 65877	672 / 2039147	0.49 (0.25-0.96)
Risk period extended to 90 days after fourth vaccine dose			
Anaphylaxis	57 / 262345	272 / 1384066	0.85 (0.56-1.29)
Ischemic cardiac event	1381 / 254126	7156 / 1344999	0.92 (0.84-1.00)
Cerebrovascular event	1623 / 255346	8439 / 1351895	0.85 (0.78-0.92)
Arterial thromboembolism	34 / 262429	291 / 1384423	0.49 (0.30-0.81)

Supplementary Table S8. Risk of adverse events after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+ year-olds during 15 September 2022 to 10 December 2022 with use of alternative risk periods.

Alternative risk period/outcome	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Deep vein thrombosis	471 / 259910	2633 / 1372343	0.85 (0.74-0.99)
Pulmonary embolism	462 / 260687	2337 / 1376399	0.76 (0.65-0.88)
Myocarditis or pericarditis	47 / 262424	240 / 1384406	0.94 (0.59-1.50)
Cerebral venous thrombosis	4 / 262627	28 / 1385436	0.79 (0.18-3.56)
Thrombocytopenia or coagulative disorder	65 / 262228	364 / 1383377	0.66 (0.45-0.96)
Guillain-Barré syndrome	4 / 262617	41 / 1385374	0.26 (0.08-0.86)
Bell's palsy	58 / 262356	358 / 1384079	0.92 (0.61-1.40)
Transverse myelitis	0 / 262642	8 / 1385498	NE
Encephalomyelitis or encephalitis	10 / 262596	52 / 1385265	0.48 (0.21-1.12)
Narcolepsy	0 / 262626	7 / 1385415	NE
Appendicitis	239 / 261365	1415 / 1379352	0.87 (0.71-1.06)
Aseptic arthritis	436 / 259638	2409 / 1370916	0.74 (0.64-0.86)
Type 1 diabetes mellitus	51 / 260485	404 / 1374537	0.73 (0.48-1.10)
Subacute thyroiditis	21 / 262567	106 / 1385086	0.77 (0.41-1.47)
Heart failure	1189 / 256874	6121 / 1357746	0.79 (0.72-0.88)
Arrhythmia	3246 / 242808	15767 / 1294964	0.91 (0.85-0.96)
Acute liver failure	29 / 262479	262 / 1384634	0.42 (0.26-0.69)
Acute kidney failure	507 / 260415	2861 / 1374549	0.64 (0.56-0.74)
Acute pancreatitis	159 / 261907	916 / 1381989	0.70 (0.55-0.89)
Erythema multiforme	4 / 262630	27 / 1385450	0.83 (0.16-4.32)
Seizure	255 / 260574	1278 / 1375293	0.99 (0.80-1.22)
Arterial aneurysm	629 / 259535	2547 / 1371468	1.03 (0.90-1.19)
Uveitis	68 / 262182	466 / 1383147	1.02 (0.69-1.52)

NE denotes not estimable.

Supplementary Table S9: Risk of cerebrovascular infarction, myocarditis and/or pericarditis after vaccination with the individual bivalent omicron-containing vaccine types as a fourth dose by sex and age groups within 28 days in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.

Outcome/subgroups	BNT BA.4-5-containing		BNT BA.1-containing		MOD BA.1-containing		Reference period		Incidence rate ratio (95% CI)		
	Events/ PYRS	Rate/ 1,000,000	Events / PYRS	Rate/ 1,000,000	Events / PYRS	Rate/ 1,000,000	Events/ PYRS	Rate/ 1,000,000	BNT BA.4-5-containing	BNT BA.1-containing	MOD BA.1-containing
Cerebrovascular infarction (including TIA)											
All	377 / 84259	343.0	246 / 38856	485.3	21 / 4189	384.3	9687 / 1853451	400.7	0.97 (0.86- 1.09)	0.98 (0.85- 1.12)	0.83 (0.54- 1.29)
Females	156 / 43643	274.0	118 / 21860	413.8	16 / 2292	535.2	4317 / 974392	339.6	0.92 (0.77- 1.10)	0.91 (0.74- 1.11)	1.27 (0.76- 2.13)
Males	221 / 40616	417.1	128 / 16997	577.3	5 / 1897	202.0	5370 / 879059	468.3	1.01 (0.87- 1.19)	1.04 (0.86- 1.26)	0.41 (0.17- 0.99)
Aged 50 to 64 years	75 / 39699	144.8	21 / 8206	196.2	2 / 1315	116.6	1716 / 806017	163.2	0.89 (0.69- 1.15)	1.20 (0.77- 1.87)	0.75 (0.19- 3.03)
Aged 65 to 79 years	180 / 32245	427.9	110 / 18751	449.7	6 / 1464	314.1	4036 / 690056	448.4	0.95 (0.81- 1.13)	1.02 (0.83- 1.25)	0.74 (0.33- 1.65)
Aged 80 years or older	99 / 7984	950.6	105 / 9726	827.6	12 / 1192	771.5	3351 / 266105	965.4	1.07 (0.86- 1.33)	0.92 (0.74- 1.13)	0.94 (0.53- 1.66)
Myocarditis or pericarditis											
All ^a	18 / 85800	16.1	9 / 40116	17.2	2 / 4281	35.8	322 / 1892114	13.0	1.05 (0.58- 1.92)	1.29 (0.61- 2.74)	3.17 (0.77- 13.11)
Females	8 / 44256	13.9	5 / 22443	17.1	2 / 2331	65.8	130 / 990933	10.1	0.87 (0.33- 2.33)	1.55 (0.58- 4.10)	6.45 (1.50- 27.82)
Males	10 / 41544	18.5	4 / 17673	17.4	0 / 1950	NE	192 / 901182	16.3	1.20 (0.56- 2.58)	0.99 (0.30- 3.28)	NE
Aged 50 to 64 years	8 / 40022	15.3	2 / 8313	18.4	1 / 1327	57.8	144 / 812580	13.6	1.30 (0.57- 2.95)	1.46 (0.34- 6.23)	5.37 (0.72- 40.12)
Aged 65 to 79 years	6 / 32993	13.9	4 / 19283	15.9	1 / 1494	51.3	117 / 706700	12.7	0.95 (0.38- 2.38)	1.04 (0.35- 3.04)	3.42 (0.46- 25.70)

Supplementary Table S9: Risk of cerebrovascular infarction, myocarditis and/or pericarditis after vaccination with the individual bivalent omicron-containing vaccine types as a fourth dose by sex and age groups within 28 days in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.

Outcome/subgroups	BNT BA.4-5-containing		BNT BA.1-containing		MOD BA.1-containing		Reference period		Incidence rate ratio (95% CI)		
	Events/ PYRS	Rate/ 1,000,000	Events / PYRS	Rate/ 1,000,000	Events / PYRS	Rate/ 1,000,000	Events/ PYRS	Rate/ 1,000,000	BNT BA.4-5-containing	BNT BA.1-containing	MOD BA.1-containing
Aged 80 years or older	0 / 8355	NE	2 / 10272	14.9	0 / 1239	NE	41 / 279247	11.3	NE	1.52 (0.31- 7.38)	NE
Myocarditis											
All	6 / 85859	5.4	2 / 40146	3.8	1 / 4283	17.9	64 / 1893405	2.6	3.74 (1.16- 12.05)	2.59 (0.52- 12.94)	12.39 (1.46- 105.47)
Females	3 / 44278	5.2	2 / 22455	6.8	1 / 2332	32.9	29 / 991433	2.2	7.10 (1.06- 47.81)	8.50 (1.24- 58.44)	59.58 (4.97- 714.53)
Males	3 / 41581	5.5	0 / 17690	NE	0 / 1951	NE	35 / 901972	3.0	2.42 (0.54- 10.83)	NE	NE
Aged 50 to 64 years	3 / 40050	5.7	0 / 8320	NE	1 / 1327	57.8	25 / 813144	2.4	4.76 (0.80- 28.37)	NE	50.46 (4.55- 559.52)
Aged 65 to 79 years	3 / 33017	7.0	1 / 19297	4.0	0 / 1495	NE	26 / 707193	2.8	3.04 (0.62- 15.00)	1.55 (0.16- 14.66)	NE
Aged 80 years or older	0 / 8361	NE	1 / 10279	7.5	0 / 1240	NE	7 / 279421	1.9	NE	16.95 (0.62- 459.83)	NE
Pericarditis											
All	14 / 85811	12.5	7 / 40123	13.4	1 / 4281	17.9	265 / 1892351	10.7	0.85 (0.43- 1.71)	1.12 (0.48- 2.64)	1.82 (0.25- 13.31)
Females	7 / 44260	12.1	3 / 22445	10.2	1 / 2331	32.9	104 / 991018	8.0	0.75 (0.25- 2.21)	0.99 (0.29- 3.34)	3.14 (0.42- 23.64)
Males	7 / 41551	12.9	4 / 17677	17.3	0 / 1951	NE	161 / 901332	13.7	0.96 (0.39- 2.38)	1.23 (0.37- 4.13)	NE

Supplementary Table S9: Risk of cerebrovascular infarction, myocarditis and/or pericarditis after vaccination with the individual bivalent omicron-containing vaccine types as a fourth dose by sex and age groups within 28 days in Danish 50+ year-olds during 15 September 2022 to 10 December 2022.

Outcome/subgroups	BNT BA.4-5-containing		BNT BA.1-containing		MOD BA.1-containing		Reference period		Incidence rate ratio (95% CI)		
	Events/ PYRS	Rate/ 1,000,000	Events / PYRS	Rate/ 1,000,000	Events / PYRS	Rate/ 1,000,000	Events/ PYRS	Rate/ 1,000,000	BNT BA.4-5- containing	BNT BA.1- containing	MOD BA.1- containing
Aged 50 to 64 years	6 / 40028	11.5	2 / 8314	18.4	0 / 1327	NE	122 / 812683	11.5	1.09 (0.43- 2.73)	1.64 (0.38- 7.07)	NE
Aged 65 to 79 years	4 / 32998	9.3	3 / 19286	11.9	1 / 1494	51.3	92 / 706793	10.0	0.75 (0.25- 2.25)	0.94 (0.27- 3.20)	4.09 (0.54- 31.00)
Aged 80 years or older	0 / 8356	NE	1 / 10274	7.5	0 / 1239	NE	35 / 279276	9.6	NE	0.78 (0.09- 6.47)	NE

BNT denotes BNT162b2, MOD mRNA-1273, NE not estimable, and PYRS total person-years. Rate/1,000,000 is the incidence rate per 1,000,000 vaccinated within 28 days. *The IRR estimates are identical to those reported in Figure 2.

Supplementary references

1. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur J Epidemiol* 2014;29(8):541–9.
2. Krause TG, Jakobsen S, Haarh M, Mølbak K. The Danish vaccination register. *Euro Surveill* 2012;17(17):20155.
3. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clinical Epidemiology* 2015;449.